Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates in

$40M up front: Skyhawk takes flight with Vertex deal

Skyhawk Therapeutics Inc., one of the early leaders in developing small-molecule drugs that target RNA, closed out the year with yet another

The Endpoints 11 : Here are some of the most promising startups in biotech. And Covid-19 isn’t ...

The Endpoints 11 : Here are some of the most promising startups in biotech. And Covid-19 isn’t going to stop them John Carroll : Editor &...

Merck doubles down on Skyhawk’s tech to drug RNA, promising $600M per autoimmune, metabolic target

Ear­ly col­lab­o­ra­tions with big-name part­ners lent Sky­hawk Ther­a­peu­tics both the en­dorse­ments and the cap­i­tal to pur­sue a small

The 20 Startups to Watch in Boston in 2020

Below are the 20 Startups to Watch in 2020. Based on factors like funding, partnerships, awards, technology licenses and more

C&EN’s 2019 10 Start-Ups to Watch

As we at C&EN present our fifth class of 10 Start-Ups to Watch, we can confirm that there are definitely hundreds, and perhaps thousands.

Bill Haney’s Skyhawk spears another marquee alliance for its work drugging RNA in Takeda neuro pact

Com­ing af­ter its Shire buy­out, Take­da has al­lied with Sky­hawk to dis­cov­er new small mol­e­cules for un­spec­i­fied neu­ro­log­i­cal

Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinic

A few years after becoming one of the first major biotechs out to drug RNA with small molecules, serial entrepreneur and filmmaker Bill Hane

A busy, buzzy Vertex finds a high-profile partner in the RNA-drugging world to launch a fresh ...

A busy, buzzy Vertex finds a high-profile partner in the RNA-drugging world to launch a fresh discovery effort

Skyhawk Therapeutics boosts Merck collab pact with added targets, upfront and biobucks

Merck has decided to double down on its research pact with startup Skyhawk Therapeutics as it expands the deal to now also cover autoimmune

The 20 under 40 : Inside the next generation of biopharma leaders

Inside the next generation of biopharma leaders – Endpoints News

Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home

With Bris­tol-My­ers Squibb’s Cel­gene buy­out all but com­plete, the BD teams are work­ing in per­fect syn­chrony now.

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene

Skyhawk Therapeutics Announces a Second Multi-Target Collaboration Agreement with Celgene to Discover and Develop Novel Small Molecules

Top 20 Life Science Startups to Watch in 2019

BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America

Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President

Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President and Graeme Smith PhD as SVP NonClinical Development

Vertex joins Skyhawk’s roster of A-list partners, securing options on RNA splicing modulators

Vertex will take full responsibility for development and commercialization of assets it licenses from Skyhawk Therapeutics.

Skyhawk Therapeutics Announces Expansion of its Collaboration Agreement with Merck

Skyhawk Therapeutics Announces Expansion of its Collaboration Agreement with Merck to Discover and Develop Novel Small Molecules that Modula

Experienced Business Leader in Biopharmaceutical Industry Joins as Chief Operating Officer

Dr. Terrance Connolly brings over 20 years of biotech operations and business development experience to his role as Chief Operating Officer

Skyhawk’s $80M Celgene deal expands remit to autoimmune

In Skyhawk’s fifth deal of the year, the company is moving into a new therapeutic area and adding $80 million to its cash reserve.

Fattening the bankroll, Bill Haney adds cancer R&D powerhouse Merck to Skyhawk’s roster

John Carroll – Editor & Founder   What­ev­er Bio­gen learned about Sky­hawk in the 6 months since it an­ted up $74 mil­lion to get a...